Regulators Sought Contempt Order Against Martin Shkreli
The FTC and seven states allege Shkreli violated a 2022 lifetime ban from the pharmaceutical industry.
Updated on Oct. 13, 2026 in Healthcare
Live Poll
Should courts have the authority to permanently ban individuals from working in an entire industry?
The Federal Trade Commission and seven states have filed a contempt motion in federal court against Martin Shkreli. Regulators allege that Shkreli violated a 2022 court order that permanently banned him from the pharmaceutical industry.
Why it matters
The motion follows claims that Shkreli continued to trade pharmaceutical stocks and comment on company management despite his lifetime ban. This legal action seeks to enforce the court-ordered restrictions stemming from a previous anti-competitive scheme.
Seven states joined the Federal Trade Commission in a federal contempt motion. This filing seeks to enforce a 2022 court order that prohibits Shkreli from participating in the pharmaceutical industry for life.
The players
Martin Shkreli
He is a former pharmaceutical executive who was previously convicted of securities fraud.
Federal Trade Commission
This independent U.S. government agency is responsible for promoting consumer protection and eliminating anti-competitive business practices.
The details
The FTC alleges that Shkreli breached his lifetime ban by publicly trading pharmaceutical stocks and broadcasting his opinions on the business management of various firms. The 2022 ban was originally imposed after a court found Shkreli responsible for an anti-competitive scheme involving the drug Daraprim.
Timeline
Martin Shkreli stood trial for securities fraud in 2017.
A court issued a lifetime pharmaceutical industry ban in 2022.
Shkreli was released from prison in May 2022.
The FTC and states filed the contempt motion on October 13, 2026.
Market Landscape
The motion to hold Shkreli in contempt extends the enforcement reach of the 2022 court order banning Martin Shkreli from the pharmaceutical industry. This action underscores the ongoing regulatory focus on monitoring the activities of individuals barred from the sector.
The legal action highlights the government's commitment to ensuring that individuals under industry bans adhere to court restrictions. Consumers and investors should note that these proceedings are part of a broader effort to prevent past bad actors from exerting influence on pharmaceutical markets.
The takeaway
Regulators remain vigilant in monitoring compliance with court-mandated industry bans. This case serves as a reminder that individuals subject to lifetime professional exclusions face significant legal consequences if they continue to engage in market-related activities.
Further reading
For more on industry oversight, see our coverage of Healthcare.
Live Poll
Should courts have the authority to permanently ban individuals from working in an entire industry?
